Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Bile Duct Cancer in the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18 years~* Histological or cytological diagnosis of cholangiocarcinoma~* Disease not amenable to surgery~* Predominant disease load in the liver (in case of extra-hepatic involvement, only patients with lymph nodes metastases are allowed)~* Naïve to locoregional or systemic treatment (but patients who develop recurrent disease after surgery are suitable)~* ECOG PS 0-1~* At least one measurable disease lesion according to RECIST v 1.1~* Life expectancy of 12 weeks or longer~* Adequate hematological, renal and hepatic function~* Platelet ≥100 x 109~* ANC ≥ 1.5 x 109~* Bilirubin ≤ 30µmol/L~* Albumin ≥ 30g/L~* ALT ≤ 3 ULN~* INR ≤ 1.5~* Serum creatinine ≤ 1.5 x ULN~Exclusion Criteria:~* Prior malignancy except cervical carcinoma-in-situ or treated basal cell carcinoma. Any cancers treated curatively \> 5 years prior to study entry are permitted.~* Patients with extra-hepatic disease other than regional lymph node metastases.~* Evidence of ascites or cirrhosis, as determined by clinical or radiologic assessment~* Biliary obstruction with no possibility of drainage~* Non-malignant disease that would render the patient unsuitable for treatment according to the protocol~* Prior treatment of chemotherapy for the cholangiocarcinoma~* Prior radiation therapy to the upper abdomen~* Complete thrombosis of the main portal vein~* Tumor volume \> 50% of the normal liver volume~* Allergy to non-ionic contrast agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SIRT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).